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OBJECTIVES The goal of this study was to determine the influence of smoking cessation on mortality after
coronary artery bypass graft surgery (CABG), which has still not been established clearly.
BACKGROUND Cigarette smoking is one of the known major risk factors of coronary artery disease.
METHODS One thousand and forty-one patients underwent CABG between 1971 and 1980. The
preoperative and postoperative smoking habits of 985 patients (95%) could be retrieved and
were analyzed in a multivariate Cox analysis.
RESULTS The median follow-up was 20 years (range 13 to 26 years). Smoking status before surgery did
not entail an increased risk of mortality: patients who had smoked before surgery and those
who had not smoked in the year before surgery had a similar probability of survival. However,
smoking cessation after surgery was an important independent predictor of a lower risk of
death and coronary reintervention during the 20-year follow-up when compared with patients
who continued smoking. In analyses adjusted for baseline characteristics, the persistent
smokers had a greater relative risk (RR) of death from all causes (RR 1.68 [95% confidence
interval 1.33 to 2.13]) and cardiac death (RR 1.75 [1.30 to 2.37]) as compared with patients
who stopped smoking for at least one year after surgery. The estimated benefit of survival for
the quitters increased from 3% at five years to 14% at 15 years. The quitters were less likely
to undergo repeat CABG or a percutaneous coronary angioplasty procedure (RR 1.41 [1.02
to 1.94]).
CONCLUSIONS Patients who continued to smoke after CABG had a greater risk of death than patients who
stopped smoking. They also underwent repeat revascularization procedures more frequently.
Cessation of smoking is therefore strongly recommended after CABG. Clinicians are
encouraged to start or to continue smoking-cessation programs in order to help smokers to
quit smoking, especially after CABG. (J Am Coll Cardiol 2000;36:878–83) © 2000 by the
American College of Cardiology
It is well established that cigarette smoking is a major
contributor to the risk of coronary heart disease (1,2).
Previous studies have shown that smoking is strongly related
to myocardial infarction (MI) (3–5) and cardiac death (6) in
the general population. A recent study has shown that
cessation of smoking after percutaneous coronary angio-
plasty (PTCA) may have an important beneficial effect on
the clinical course after the procedure (7). Some studies
suggested that patients who continue to smoke are at greater
risk for atherosclerosis of vein grafts than nonsmokers (8,9),
whereas two other studies show a beneficial effect on clinical
events after coronary artery bypass surgery (CABG) (10,11).
However, the effects of smoking and smoking cessation
after CABG on mortality have not been clearly established.
In this study we assessed the relation between smoking
cessation and the mortality risk after CABG and deter-
mined whether smoking cessation after CABG affected the
need for repeat revacularization procedures. To this end a
group of 985 patients who were operated on between 1971
and 1980 were, therefore, followed during a 20-year period.
METHODS
Patient population. All 1,041 consecutive patients who
underwent a first CABG surgery between February 1971
and June 1980 at the Thoraxcenter were considered for this
study. The bypass grafts in all these patients were all of
saphenous vein material only. The medium-term and long-
term survival probabilities of this group have been published
previously (12–14). The smoking habits before and after
surgery could be retrieved from 985 patients. The popula-
tion consisted of 866 men (88%) and 119 women (12%)
with a mean age of 53 and 55 years, respectively. Multivessel
disease was present in 81% of the patients, and impaired left
ventricular ejection fraction (,55%) was found in 27% of
the patients.
Follow-up procedure. Follow-up procedure for vital status
was obtained by contacting the civil registry in writing and
was complete in 98%. Median follow-up was 20 years (range
13 to 26 years). Mortality was divided into perioperative
mortality (death occurring within 28 days after surgery) and
late mortality. The latter was subdivided into: 1) death at
re-CABG or PTCA; 2) acute cardiac death (within 1 h after
beginning of complaints, believed to be of cardiac origin); 3)
death caused by MI (ascertained by enzyme measurement
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and electrocardiogram); 4) death caused by chronic cardiac
failure; 5) death from a noncardiac cause; 6) unknown cause
of death. The cause of death was determined by checking
our own hospital records, by contacting the referring hos-
pitals (for autopsy reports or letters to the general practitio-
ner) or the attending general practitioner.
Smoking behavior. In 1981 all patients were queried about
their smoking status before surgery and after surgery. At
that time, May 1981, 64 (6.2%) of the original group of
1,041 patients had died and another 8 had moved abroad
(14). The remaining patients were sent a questionnaire to
ascertain their postoperative condition and smoking habits.
We were able to retrieve the preoperative and postoperative
(recorded at least one year after surgery) smoking habit
status of 985 patients (95%) (Fig. 1). The small number of
patients (20) who started to smoke after CABG were
excluded from the present analysis. In the 56 patients whose
smoking status at least one year after CABG was unknown,
48 of the 56 patients had died at the time when the patients
were queried about their smoking behavior (perioperative
mortality: 12 patients; one-year mortality: 33 patients, of
which 25% were noncardiac). The baseline characteristics of
these 56 patients were similar to the group of patients in
whom the smoking was known. The median duration
between CABG and the assessment of smoking behavior
was 2.8 years (range 11 months to 9.5 years). The study
population was divided into two groups: smokers and
nonsmokers (ex- and never smokers) in the year before
CABG; the smokers before surgery were further subdivided
into quitters who had stopped smoking in the first year after
the index CABG (most immediate after CABG) and
persistent smokers, those who smoked before CABG and
continued to smoke for at least one year after CABG.
Data management and statistics. Differences between the
smokers and nonsmokers, as well as quitters and persistent
smokers, were calculated by means of the Student t test for
continuous data or the chi-square test for categorical data.
Preselected variables were age, sex, extent of vessel disease,
preoperative ejection fraction and complete or incomplete
revascularization. A vessel was considered diseased when the
luminal diameter narrowing of at least 50% was seen in
more than one projection. Ejection fraction was angio-
graphically calculated in 705 patients and considered im-
paired if less than 55%. A complete revascularization was
defined as “no remaining main artery stenosis of at least
50%.” The survival data were analyzed using the Kaplan
Meier method. The log-rank test was used to compare
survival curves. Univariable Cox proportional-hazard model
was used to estimate the unadjusted relative risks (RR) for
nonsmokers as compared with smokers at the time of
surgery and to compare quitters and persistent smokers after
surgery. A multivariate Cox model adjusting for the prese-
lected clinical and angiographic parameters was used to
estimate the adjusted RRs.
RESULTS
The baseline clinical characteristics of the smokers and
nonsmokers are shown in Table 1. Smokers at the time of
surgery were four years younger and more often men
compared with nonsmokers. The clinical characteristics of
quitters and persistent smokers were comparable except for
a larger proportion of multivessel disease among the persis-
tent smokers.
Median follow-up was 20 years (range 13 to 26 years).
Death occurred in 234 (54%) of the 429 nonsmokers at the
time of surgery, of which 65% were due to cardiac causes.
Of the 556 smokers before CABG, 311 (56%) died within
20 years, of which 65% were due to cardiac causes (Table 2).
Of the 238 patients who stopped smoking after CABG, 109
(46%) died within 20 years, whereas 202 (64%) of the 318
persistent smokers died during the follow-up. A cardiac
cause of death was found in 62% of the quitters and in 68%
of the nonquitters.
Mortality. In the univariable analysis (Table 3), the persis-
tent smokers had higher risks of death from all causes (RR
1.56 [95% confidence interval [CI], 1.24 to 1.97]) and also
from cardiac death (RR 1.70 [95% CI, 1.26 to 2.29])
compared with the quitters. The smoking habit was the
strongest predictor of mortality in a stepwise multivariate
Cox analysis, even when all other baseline risk factors were
forced into the model. The persistent smokers had a
significantly greater risk of death from all causes (RR 1.68,
95% CI, 1.33 to 2.13) and of cardiac death (RR 1.75 [95%
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
CI 5 confidence interval
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary
angioplasty
RR 5 relative risk
Figure 1. Flow-chart of the subdivision of the smoking habits of 1,041
consecutive patients who underwent a first CABG surgery between 1971
and 1980. CABG 5 coronary artery bypass graft surgery.
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CI, 1.30 to 2.37) compared with patients who quit smoking
after CABG.
The estimated survival curves for the patients who quit
smoking and those who continued to smoke diverged
approximately four years after the index operation, and the
difference between the two curves increased throughout the
follow-up period (Fig. 2). The estimated benefit in survival
associated with the cessation of smoking increased from 3%
at 5 years (98% vs. 95%), to 10% at 10 years (88% vs. 78%)
and 15% at 15 years (70% vs. 55%). After 20 years the
benefit was still 8% (47% vs. 39%).
Repeat procedure. Repeat CABG was performed in 27%
of the patients who quit smoking and 31% of the persistent
smokers. During follow-up, repeat coronary artery revascu-
larization (either CABG or PTCA) was performed more
frequently among the persistent smokers compared with
quitters (RR 1.42 [95% CI, 1.05 to 1.90]). An identical
survival rate and a repeat coronary artery revascularization
rate were found between the smokers and nonsmokers at the
time of surgery. Also, when adjusted for baseline character-
istics, repeat CABG or PTCA was more frequently found
among the persistent smokers compared with patients who
quit smoking (RR 1.41 [95% CI, 1.02 to 1.94]).
The Kaplan-Meier survival curves representing freedom
from repeat coronary interventions are shown in Figure 3.
Due to the low intervention rates in both groups, the rates
were similar up to 10 years, after which the curves for
quitters and persistent smokers diverged.
DISCUSSION
This study examined the influence of patients’ smoking
habits before and after CABG on mortality and repeat
revascularization procedures. The relatively high proportion
Table 1. Baseline Characteristics of 985 Patients Undergoing Successful Coronary Artery Bypass
Surgery According to Smoking Status
Event
Nonsmokers at
Time of Surgery
(n 5 429)
Smokers at Time of Surgery
All
(n 5 556)
Quitters
(n 5 238)
Persistent Smokers
(n 5 318)
Age (yrs) 55.1 51.2* 51.7 50.8
Men % 83 92* 90 93
Number of bypass grafts 2.8 2.6 2.6 2.7
Vessel disease %†
1-vessel 17 20 26 16
2-vessels 32 29 25 35
3-vessels 42 42 40 43
Left main 9 7 9 6
Ejection fraction %
Normal 58 58 58 58
Moderate (30–55%) 25 22 23 22
Poor (#30%) 3 3 2 3
Unknown‡ 15 17 17 17
Revascularization %
Complete 79 79 80 79
Incomplete 21 21 20 21
Quitters were defined as patients who quit smoking for at least one year after the index procedure and persistent smokers as
patients who were still smoking at least one year after the index procedure.
*p , 0.05 comparing smokers vs. nonsmokers; †when comparing quitters and persistent smokers (2 3 4 table) a p , 0.05
was found; ‡due to insufficient quality or absence of the ventriculogram.
Table 2. Number of Events (%)
Event %
Nonsmokers at
Time of Surgery
(n 5 429)
Smokers at Time of Surgery
All
(n 5 556)
Quitters
(n 5 238)
Persistent Smokers
(n 5 318)
Death from all causes 54 56 46 64
Sudden death 26 29 26 30
Fatal myocardial infarction 14 13 14 12
Reintervention death 8 5 5 4
Other cardiac death 17 19 18 22
Noncardiac death 26 25 26 23
Unknown death 9 10 12 9
PTCA 13 11 9 13
Repeat CABG 28 29 27 31
PTCA or repeat CABG 35 33 30 36
CABG 5 coronary artery bypass graft surgery; PTCA 5 percutaneous transluminal coronary angioplasty.
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of smokers at the time of surgery (56%) in our study group
is due to the fact that our patients date from the 1970s.
Since health care programs in the 1980s encouraged patients
to stop smoking, the percentage of coronary patients who
smoke has steadily decreased to around 30% in the Neth-
erlands. However, this figure still compares unfavorably
with other West-European or North American countries
(15).
There has been much controversy about whether smokers
should receive the same opportunities for CABG as non-
smokers (16,17). Discussion on this subject was mainly
based on the consistent finding that continued smoking
after CABG increased clinical complications, such as MI
and repeat coronary revascularization. Voors et al. (11)
demonstrated that, at one year after surgery, smokers had
more than twice the risk for MI and reoperation as
compared with patients who had stopped smoking since
surgery. Previous short- and medium-term studies or stud-
ies on subpopulations have shown improved survival in
patients who stops smoking after MI (4,18–22). A recent
publication of the Mayo Clinic investigators (7) showed an
increased RR of 44% of death among the persistent smokers
compared with quitters after percutaneous coronary revas-
cularization. However, to the best of our knowledge, the
benefit of smoking cessation on the risk of death after
CABG is still unknown.
Survival. In our study, after adjustment for clinical and
angiographic characteristics, the persistent smokers had a
greater risk of death from all causes as compared with
patients who stopped smoking after surgery during the very
long follow-up of 20 years. Improved survival rates were
seen from approximately four years after CABG. During
that time the risk of death from any cause was 68% greater
in patients who persisted in smoking after CABG than it
was in those who quit. The estimated survival curves for the
two groups diverged at four to five years after surgery and
continued to diverge throughout the entire follow-up pe-
riod. The benefit of smoking cessation on mortality may be
explained largely by the reduction in cardiac deaths since the
RR of cardiac death was 75% higher for the persistent
smokers than it was for the quitters. Voors et al. (11) found
a similar RR of mortality of 1.7. However, probably due to
the limited number of patients, this risk was statistically not
significant.
Repeat procedure. In agreement with the findings of
Voors et al. (11), we found that persistent smokers do need
more repeat coronary revascularization procedures than
quitters. In that study patients who continued to smoke
after surgery had a 41% higher risk of undergoing a repeat
CABG or a PTCA. In our study coronary reintervention up
to 10 years was rare after CABG. Thereafter, this incidence
increased, probably due to graft atherosclerosis and progres-
sion of native coronary artery disease. Nevertheless, the
reintervention rates diverged starting at 10 years postoper-
ative in favor of the quitters when compared with persistent
smokers.
Smoker’s paradox. Many investigations have demonstrated
that smoking is associated with higher rates of heart disease.
It is, therefore, surprising that smoking habits at the time of
surgery did not significantly influence survival and reinter-
vention rates during the follow-up period. In addition
Hasdai et al. (7) reported that smokers had fewer adverse
Figure 2. Twenty-year survival from all causes curves for patients who quit
smoking after CABG, persistent smokers after CABG and nonsmokers.
CABG 5 coronary artery bypass graft surgery.
Figure 3. Twenty-year freedom from a coronary reintervention (coronary
artery bypass graft surgery or percutaneous transluminal coronary angio-
plasty) for patients who quit smoking and persistent smokers after coronary
artery bypass graft surgery.
Table 3. Univariable and Adjusted Relative Risks of Total
Mortality, Cardiac Death, Repeat Coronary Bypass Surgery or
Coronary Angioplasty
Event
Smokers vs.
Nonsmokers
Persistent
Smokers vs.
Quitters
Deaths from all causes
Unadjusted relative risks 1.04 0.88–1.22 1.56 1.24–1.97
Adjusted relative risks* 1.18 0.99–1.40 1.68 1.33–2.13
Cardiac death
Unadjusted relative risks 1.05 0.85–1.30 1.70 1.26–2.29
Adjusted relative risks* 1.14 0.91–1.41 1.75 1.30–2.37
PTCA
Unadjusted relative risks 0.78 0.55–1.12 1.50 0.89–2.53
Adjusted relative risks* 0.66 0.46–0.97 1.56 0.88–2.79
Repeat CABG
Unadjusted relative risks 1.00 0.79–1.27 1.38 1.01–1.89
Adjusted relative risks* 0.82 0.64–1.04 1.42 1.01–1.97
Repeat CABG/PTCA
Unadjusted relative risks 0.91 0.74–1.13 1.42 1.05–1.90
Adjusted relative risks* 0.76 0.61–0.95 1.41 1.02–1.94
*Adjusted for age, gender, vessel disease, ejection fraction, complete revascularization.
CABG 5 coronary artery bypass graft surgery; PTCA 5 percutaneous translu-
minal coronary angioplasty.
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events at the time of a PTCA than nonsmokers. Other
studies such as the Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded Coronary Ar-
teries trial (23) have speculated on the paradoxical beneficial
effects of smoking on thrombolytic therapy after MI. In
these studies the better prognosis for smokers was mainly
explained by the difference in clinical baseline characteristics
such as an age difference. After adjustment for all clinical
baseline characteristics, these studies showed no significant
difference in mortality between smokers and nonsmokers. In
our study the similarity in risk of death and reintervention
rate between the two groups cannot completely be explained
by these baseline parameters, as the smokers were only four
years younger than nonsmokers. Another explanation could
be selection bias since many smokers tend to die of fatal MIs
before they having the chance to undergo CABG (24).
Thus, those operated on are different from the entire
smokers cohort with coronary artery disease. Moreover, only
patients who survived the immediate postoperative period
were included in our study, which could have caused further
selection. Another explanation may be that CABG facilities
were scarce at the time, causing long waiting lists. Only the
survivors of the waiting time were operated on.
Finally, our data do not support the proposal that
smokers should receive fewer opportunities for CABG than
nonsmokers because the survival rates of nonsmokers and
smokers were similar at the time of surgery.
The study consisted of patients who underwent CABG
using vein grafts in the 1970s. To extrapolate the findings of
this study to current practice, it needs to be realized that
operation techniques have been changed, and present day
populations are different. Total arterial revascularization is
currently propagated to prevent premature death due to
graft sclerosis. This study has some limitations. We did not
record the number of cigarettes smoked. Second, there may
have been other factors intercorrelating with smoking be-
havior that we did not record. For example, smoking
cessation could be accompanied with other life style changes
such as a diet. The Multiple Risk Factor Intervention Trial
study group has investigated that, in 12,866 high-risk men,
smoking cessation was the strongest predictor of lower rates
of coronary disease as compared with other changes in risk
factors, such as cholesterol and blood pressure lowering
interventions (25). However, the effect of risk factors, such
as diabetes and hypercholesterolemia, was not yet clearly
established in the 1970s. Only variables already known to
influence survival at that time, such as left ventricular
function and extent of vessel disease, were consistently
reported and therefore used for further analysis. Smoking
status was assessed by asking patients about their smoking
behavior and, if necessary, from the hospital records. This
remains a possible cause of bias, as we were not able to check
reported data against biochemical validation. However,
self-reports of smoking in observational studies in an adult
population such as this have a high sensitivity and specificity
(26).
Conclusions. Our results strongly indicate that, after
CABG, patients who do not stop smoking have a markedly
elevated risk of premature death and a higher rate of repeat
revascularization procedures compared with those who do
stop. Cessation of smoking is therefore strongly recom-
mended after CABG, and clinicians are encouraged to start
or continue smoking cessation programs (27) in order to
help patients stop smoking.
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